9/26/2013

Merck KGaA said it would initiate a new late-stage trial of its lung cancer vaccine tecemotide, previously called Stimuvax, which did not meet the goals of a previous Phase III study. The new trial will involve patients with locally advanced Stage 3 nonsmall-cell lung cancer.

Related Summaries